Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- AstraZeneca, MSD to Copromote Lynparza from July
June 29, 2018
- Nippon Shinyaku’s Sakigake-Designated DMD Med Boosts Dystrophin Protein Production in Clinical Studies
June 29, 2018
- BMS Ties Up with Nagoya Univ. for Immuno-Oncology Biomarker Research
June 29, 2018
- Eliquis Significantly Lowers Stroke Risk vs Warfarin: Real-World Data
June 29, 2018
- Mitsubishi Tanabe, Janssen Revise Copromotion Framework for Stelara
June 29, 2018
- JT, Torii Ditch Pruritus Candidate Development
June 29, 2018
- Takeda Shareholders Strike Down Dissident Group’s Proposal
June 28, 2018
- Japan’s 1st Rituxan Biosimilar Boasts 13% Share: Sandoz Country Head
June 28, 2018
- DPP-4/SGLT2 Combo Sujanu Most Heavily Pitched for GPs in May: Anterio
June 28, 2018
- AbbVie Eyes Global Simultaneous Launch for Autoimmune Disease Treatments: Exec
June 28, 2018
- Keytruda’s MSI-H Cancer Indication to Be Reviewed Under Conditional Early Approval System
June 28, 2018
- Chugai Chairman Prods Drug Makers to Innovate, Chides Calls for Relaxed Pricing
June 27, 2018
- FDA Decision on Shionogi’s Single-Dose Drug Expected by Dec. 24
June 27, 2018
- Rohto Takes 15% Stake in Shionogi’s Consumer Healthcare Unit
June 26, 2018
- Lonsurf Cuts Risk of Death by 31% in Metastatic Gastric Cancer
June 26, 2018
- Meiji, Hiroshima Univ. Spinout Hook Up on Cell Therapies for Osteoarthritis
June 26, 2018
- Xofluza Likely to Jolt Japan Flu Market This Winter
June 25, 2018
- J-TEC Enters License Agreement on Low-Cost Manufacturing of CAR-T Cells with 2 Universities
June 25, 2018
- Kowa Sues Towa for Damages Caused by Livalo Generics
June 25, 2018
- Generic Specialist Ohara to Develop Novel Liver Cirrhosis Treatment Licensed from Japanese Startup
June 25, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…